Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Elacestrant in Preoperative Setting, a Window of Opportunity Study (ELIPSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04797728
Recruitment Status : Recruiting
First Posted : March 15, 2021
Last Update Posted : June 10, 2021
Radius Health, Inc.
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group

Brief Summary:
ELIPSE is a window of opportunity, prospective, multicenter, phase 0 trial which evaluates the effect of Elacestrant on proliferation after 4 weeks of treatment in postmenopausal women with Estrogen Receptor-positive (ER+) and Human Epidermal Growth Factor Receptor 2-negative (HER2-negative) early breast cancer (BC) amenable to surgery.

Condition or disease Intervention/treatment Phase
Breast Cancer Hormone Receptor Positive Breast Carcinoma Drug: Elacestrant Early Phase 1

Detailed Description:

The main hypothesis is that Elacestrant induces a significant proliferative arrest (Ki67 ≤ 2.7%) in ER+ and HER2-negative BC naïve to Endocrine Therapy (ET). To test this hypothesis, a total of 24 patients will be recruited.

Secondary objectives will include correlative molecular and histological analyses at the tumor tissue, changes in Ki67 and the identification of molecular biomarkers and gene signatures of response to Elacestrant. Molecular analysis of tumor circulating DNA (ctDNA) in blood will be also performed.

The study population consists of postmenopausal women with cT1c-3 (minimal 15 mm of largest diameter) cN0 cM0, ER+ and HER2-negative breast operable tumors.

Patients who fulfil all eligibility criteria will then start treatment in Elacestrant monotherapy cohort as follows: Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD). After 4 weeks (+/- 2 days) of Elacestrant treatment, surgery will be performed in accordance to local practice. If the tumor is not surgically removed after 4 weeks (+/-3 days), a tumor biopsy will be obtained. In this case, patients may continue further neoadjuvant treatment under physicians' criteria.

Two biopsies of the same lesion will be mandatory: first the screening sample and second the surgical sample. A core biopsy will be collected if surgery is not performed for any reason. Complete Cell Cycle Arrest (CCCA) (determined by Ki67 ≤ 2.7%) and relative changes in the PAM50 subtypes in tumor samples will be analyzed at baseline and after 4-weeks of Elacestrant therapy at central laboratory. Ki67 status at baseline will be performed at local sites for inclusion criteria (Ki67 at diagnostic ≥10%). Extensive RNA-based and blood analyses will be performed in tumor specimens at the same timepoints.

Safety assessments will include the incidence, nature, and severity of Adverse Events (AEs) and laboratory abnormalities graded per the NCI CTCAE v.5.0

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Elacestrant in Preoperative Setting, a Window of Opportunity Study
Actual Study Start Date : May 9, 2021
Estimated Primary Completion Date : March 30, 2022
Estimated Study Completion Date : March 30, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Elacestrant
400 mg given orally (PO), once a day, in a continuous schedule (QD). 4 weeks (+/- 2 days) of elacestrant treatment
Drug: Elacestrant
Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)

Primary Outcome Measures :
  1. Complete Cell Cycle Arrest [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    Ki67 ≤ 2.7%

Secondary Outcome Measures :
  1. PAM50 (Prediction Analysis of Microarray 50) subtype change [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    PAM50 subtype changes upon elacestrant therapy

  2. Gene expression change (post-treatment/pre-treatment) [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    Differential expression (mean suppression = 100 - [geometric mean (post-treatment / pre-treatment · 100)]) of 11 proliferative genes from PAM50 (BIRC5, CCNB1, CDC20, CDCA1, CEP55, KNTC2, MKI67, PTTG1, RRM2, TYMS and UBE2C).

  3. Adverse Events [ Time Frame: Until End of Study Visit (7-28 days after surgery) ]
    Frequency and severity of adverse events (evaluated according to CTCAE v.5.0.) and frequency of interruptions due to treatment toxicity.

  4. Global gene expression changes [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    Relative changes of expression 770 genes across of 23 categories of BC tumor biology after 4 weeks of treatment. This study will be performed using the Nanostring nCounter Breast 360TM panel

  5. Gene expression-based signature of response [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    To derive a new gene expression-based signature of response to Elacestrant.

  6. Celularity/Tumor Infiltrating Lymphocytes (CelTIL) score [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    CelTIL score = -0.8 × tumor cellularity (in %) + 1.3 × TILs (in %). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect a range from 0 to 100 points. TILs determination will be quantified according to the 2014 Guidelines developed by the International TILs Working Group

  7. Mean change in Ki67 [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    Mean change in Ki67 values per central assessment before and after therapy and its 95% confidence interval (CI).

  8. Changes in the distribution of somatic mutations [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    To identify changes in the distribution of somatic mutations (e.g. PIK3CA, ESR1) between basal and surgery samples

  9. ctDNA (post-treatment/pre-treatment) [ Time Frame: After 4 weeks (+/- 2 days) of elacestrant therapy ]
    Quantification of ctDNA (post-treatment/pre-treatment)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written and signed informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures.
  2. Age ≥ 18 years.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  4. Postmenopausal women defined either by:

    1. Age ≥60,
    2. Age < 60 and amenorrhea for ≥ 12 months and FSH and E2 plasmatic levels in the post-menopausal range per local standards or
    3. Prior bilateral oophorectomy (≥ 30 days before Day 1 of the study treatment).
  5. Histologically confirmed invasive breast carcinoma eligible for surgery with all the following characteristics:

    1. Primary tumor diameter of at least 15 mm (cT1c-3) as measured by breast US.
    2. No regional lymph node metastases by imaging or clinical examination (cN0).
    3. ER+ tumors, irrespective of PgR status, (nuclear stain >1%) as assessed locally, defined by the most recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) clinical practice guidelines.
    4. HER2-negative status, as assessed locally, defined by the most recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP)
    5. In case of multifocal tumors (defined as the presence of two or more foci of cancer within the same breast quadrant), the largest lesion must be measured in at least one dimension of minimal 15 mm per US. This lesion will be designated as 'target' lesion for all subsequent evaluations. ER+ and HER2-negative status must be documented in all the tumor foci if they are independent of the target lesion (does not apply to small tumoral foci around the main lesion).
    6. Cells staining positive for Ki67 ≥ 10% as locally assessed.
    7. Available pre-treatment formalin-fixed paraffin-embedded (FFPE) tumor specimen or possibility to obtain one. Minimal sample requirements are: at least 2 tumor cylinders with a minimal tissue surface of 10 mm2, containing ≥10% tumor cells, enough to obtain at least 2 cuts of 10 μm each. Tumor cylinder will be mandatory.
  6. No clinical or radiographic evidence of distant metastases (M0).
  7. Adequate hematologic and organ function within 14 days before the first study treatment on Day 1, defined by the following:

    1. Neutrophils (ANC ≥1500/μL).
    2. Hemoglobin ≥9 g/dL (with no need for transfusions).
    3. Platelet count ≥100000/μL.
    4. Serum albumin ≥3 g/dL.
    5. Calculated creatinine clearance of ≥60 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation:

      (140 - age) x (weight in kg) x 0.85 72 x (serum creatinine in mg/dL)

    6. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN and activated partial thromboplastin time (aPTT) within therapeutic range. History of deep thrombotic episodes or pulmonary embolism, or incremental risk for thrombosis at investigator criteria.
    7. Potassium, total Calcium (corrected for serum albumin), and Sodium with institutional normal limits or corrected with normal limits with supplement before first dose of study medication.
  8. Ability to swallow study drug and comply with study requirements.
  9. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.

Exclusion Criteria:

  1. Inoperable locally advanced or inflammatory breast cancer.
  2. Metastatic (Stage IV) breast cancer.
  3. Synchronous invasive bilateral or multicentric breast cancer.
  4. Patients requiring immediate neoadjuvant chemotherapy or immediate surgical intervention.
  5. Patients who have undergone sentinel lymph node biopsy or tumor excisional biopsy prior to study treatment.
  6. Prior malignancy within 3 years prior to randomization, except curatively treated non-melanoma skin cancer, in situ cervical cancer or adequately treated Stage I or II cancer from which the patient is currently in complete remission or other cancer from which the patient has been disease-free for 2 years.
  7. Congenital long QT syndrome or screening QT interval corrected using Fridericia's formula (QTcF) > 480 milliseconds or any clinically significant cardiac rhythm abnormalities.
  8. Liver function tests documented within the screening period and on Day 1 of treatment period:

    1. Total bilirubin >1.5x the upper limit of normal unless the patient has documented non-malignant disease (e.g. Gilbert´s syndrome) for whom conjugated bilirubin must be under ULN.
    2. AST and ALT >2.5x ULN.
    3. Alkaline phosphatase ALP >2x ULN.
  9. Concurrent, serious, uncontrolled infections or current known infection with HIV (testing is not mandatory).
  10. Known hypersensitivity to any of the study drugs, including excipients.
  11. History or clinical evidence of any liver or biliary pathology including cirrhosis, infectious disease, inflammatory conditions, steatosis, or cholangitis (including ascending cholangitis, primary sclerosing cholangitis, obstruction, perforation, fistula of biliary tract, spasm of sphincter of Oddi, biliary cyst or biliary atresia).
  12. Known clinically significant history active viral or other hepatitis (e.g., positive for hepatitis B surface antigen [HBsAg] or hepatitis C virus [HCV] antibody at screening), current drug or alcohol abuse, or cirrhosis.

    • Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [HBcAg] antibody test) are eligible.
    • Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  13. Chronic adrenal failure or is receiving concurrent long-term corticosteroid therapy. The following corticosteroid uses are permitted: single doses, topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airway diseases), eye drops or local injections (e.g. intra-articular).
  14. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to swallow pills.
  15. History of or clinical evidence of significant co-morbidities that, in the judgment of the investigator, may interfere with the conduction of the study, the evaluation of response, or with informed consent.
  16. Received an investigational product or been treated with an investigational device within 30 days prior to first drug administration or plans to start any other investigational product or device study within 30 days after last drug administration.
  17. Previous hormonal treatments for other indications such as osteoporosis, breast cancer prevention, hormonal substitutive therapy, such as raloxifen, tamoxifen, estrogen, progestins must have ended at least 24 months prior to trial registration. If a patient is on natural products known to contain progestins, they must be stopped 14 days prior to beginning study treatment.
  18. Used any prescription medication during the prior 1 month that the investigator judges is likely to interfere with the study or to pose an additional risk to the patient in participating.
  19. Major surgical procedure or significant traumatic injury within 30 days prior to enrollment.
  20. Patients with thromboembolic risks.
  21. Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04797728

Layout table for location contacts
Contact: Fernando Salvador, PhD +34 616 194 478
Contact: Laura Creus

Layout table for location information
ICO Badalona Recruiting
Badalona, Barcelona, Spain, 08916
Contact: Mireia Margeli         
Principal Investigator: Mireia Margeli         
Hospital General de Catalunya Recruiting
Sant Cugat Del Vallès, Barcelona, Spain, 08195
Contact: Xavier Gonzalez         
Principal Investigator: Xavier Gonzalez         
Hospital Universitari Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Contact: Meritxell Bellet         
Principal Investigator: Meritxell Bellet         
Hospital Clinic Barcelona Recruiting
Barcelona, Spain, 08036
Contact: Montserrat Muñoz         
Principal Investigator: Montserrat Muñoz, MD         
Sponsors and Collaborators
SOLTI Breast Cancer Research Group
Radius Health, Inc.
Layout table for additonal information
Responsible Party: SOLTI Breast Cancer Research Group Identifier: NCT04797728    
Other Study ID Numbers: ELIPSE (SOLTI-1905)
First Posted: March 15, 2021    Key Record Dates
Last Update Posted: June 10, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases